loading...| Preferred Name |
Olaparib |
|
| Synonyms |
|
|
| Definitions |
A small molecule inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential chemosensitizing, radiosensitizing, and antineoplastic activities. Olaparib selectively binds to and inhibits PARP, inhibiting PARP-mediated repair of single strand DNA breaks; PARP inhibition may enhance the cytotoxicity of DNA-damaging agents and may reverse tumor cell chemoresistance and radioresistance. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins and can be activated by single-stranded DNA breaks. |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C71721 |
|
| Accepted_Therapeutic_Use_For |
adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced epithelial ovarian, fallopian tube or primary peritoneal cancer; deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer |
|
| ALT_DEFINITION |
A substance being studied in the treatment of breast, ovarian, and prostate cancers caused by mutations (changes) in the BRCA1 and BRCA2 genes. It is also being studied in the treatment of other types of cancer. It blocks an enzyme involved in many functions of the cell, including the repair of DNA damage. DNA damage may be caused by normal cell actions, UV light, some anticancer drugs, and radiation used to treat cancer. AZD2281 may cause cancer cells to die. It is a type of targeted therapy agent and a type of poly (ADP-ribose) polymerase inhibitor. |
|
| CAS_Registry |
763113-22-0 |
|
| Chemical_Formula |
C24H23FN4O3 |
|
| code |
C71721 |
|
| Contributing_Source |
CTRP FDA |
|
| definition |
A small molecule inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential chemosensitizing, radiosensitizing, and antineoplastic activities. Olaparib selectively binds to and inhibits PARP, inhibiting PARP-mediated repair of single strand DNA breaks; PARP inhibition may enhance the cytotoxicity of DNA-damaging agents and may reverse tumor cell chemoresistance and radioresistance. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins and can be activated by single-stranded DNA breaks. |
|
| Display_Name |
Olaparib |
|
| FDA_UNII_Code |
WOH1JD9AR8 |
|
| in_subset |
http://purl.obolibrary.org/obo/NCIT_C63923 http://purl.obolibrary.org/obo/NCIT_C177537 http://purl.obolibrary.org/obo/NCIT_C176424 http://purl.obolibrary.org/obo/NCIT_C116977 http://purl.obolibrary.org/obo/NCIT_C116978 http://purl.obolibrary.org/obo/NCIT_C128784 |
|
| Is_Value_For_GDC_Property | ||
| label |
Olaparib |
|
| Legacy Concept Name |
PARP_Inhibitor_AZD2281 |
|
| Maps_To |
Olaparib |
|
| NCI_Drug_Dictionary_ID |
560191 |
|
| PDQ_Closed_Trial_Search_ID |
560191 |
|
| PDQ_Open_Trial_Search_ID |
560191 |
|
| Preferred_Name |
Olaparib |
|
| prefixIRI |
NCIT:C71721 |
|
| prefLabel |
Olaparib |
|
| Semantic_Type |
Pharmacologic Substance |
|
| UMLS_CUI |
C2316164 |
|
| subClassOf |